Todd Watanabe, President and Chief Executive Officer of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), filed a Form 4 on November 4, 2026, disclosing the sale of 4,377 shares of common stock on November 2, 2026, to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Key Highlights

  • Transaction date: 4,377 shares of common stock were disposed of on November 2, 2026, with transaction code "S."
  • Weighted average price: Shares were sold at a weighted average price of $31.8634, with individual transactions ranging from $31.57 to $32.23, inclusive.
  • Purpose of sale: According to the filing, the sale represents shares sold to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.
  • Direct beneficial ownership following transaction: 712,826 shares of common stock held directly after the reported transaction.
  • Indirect holdings: Watanabe also holds shares indirectly through two trusts (25,410 shares each), Watanabe Ventures, LLC (57,358 shares), and The Watanabe 2016 Irrevocable Trust (124,956 shares).
  • Disclaimers on indirect holdings: The filing states that Watanabe "disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein" for all indirectly held positions.

Arcutis CEO Todd Watanabe: RSU Vesting Triggers Tax-Related Share Sale

According to the Form 4 filed with the SEC on November 4, 2026, Todd Watanabe, identified in the filing as President and Chief Executive Officer of Arcutis Biotherapeutics, Inc., disposed of 4,377 shares of common stock on November 2, 2026. The filing states that the sale was made "to cover tax withholding obligations in connection with the vesting of Restricted Stock Units." The shares were sold in multiple transactions at prices ranging from $31.57 to $32.23, inclusive, with a weighted average sale price of $31.8634 reported in the filing.

Following the reported transaction, Watanabe directly holds 712,826 shares of Arcutis common stock, according to the filing. In addition to direct holdings, the filing discloses several indirect positions: 25,410 shares held by The John Franklin Watanabe Trust, of which Watanabe is trustee; 25,410 shares held by The Anderson Prest Watanabe Irrevocable Trust, of which Watanabe is also trustee; 57,358 shares held by Watanabe Ventures, LLC, where Watanabe serves as Chief Operating Officer; and 124,956 shares held by The Watanabe 2016 Irrevocable Trust, of which Watanabe's children are beneficiaries.

For all indirectly held positions, the filing includes a disclaimer stating that Watanabe disclaims beneficial ownership except to the extent of his pecuniary interest, and that inclusion in the report "shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes." The filing was signed by Latha Vairavan as Attorney-in-Fact for Todd Franklin Watanabe.

What Was Disclosed

Arcutis Biotherapeutics President and CEO Todd Watanabe reported a tax-withholding-related sale of 4,377 shares of common stock at a weighted average price of $31.8634 on November 2, 2026, leaving him with 712,826 shares held directly and additional shares held indirectly through several trusts and an LLC.